Novo’s Latest Obesity Flop Prompts Investors to Call for a Pivot
Novo Nordisk A/S’s next-generation weight-loss drug CagriSema isn’t even on the market yet, but the company’s chief executive officer is already batting back suggestions that the drug is obsolete following...
By Naomi Kresge · Bloomberg
Novo Nordisk A/S’s next-generation weight-loss drug CagriSema isn’t even on the market yet, but the company’s chief executive officer is already batting back suggestions that the drug is obsolete following the release of disappointing trial results on Monday. Among investors, news of CagriSema’s poor showing against Eli Lilly & Co.’s Zepbound sparked calls for a radical shift.